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INTRODUCTION
Diabetes mellitus is a multifaceted serious illness involving 
endocrine pancreas with multiple complications and affecting 
more than 285 million people worldwide, and is considered as one 
of the three leading causes of death in the world.[1] In diabetes, 
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ABSTRACT
Stereospermum suaveolens is a folk remedy for the treatment of diabetes and liver disorders in southern parts of India. In the present 
study, the protective effect of the ethyl acetate fraction of ethanol extract from S. suaveolens against hepatic oxidative stress was evaluated 
in streptozotocin (STZ)‑induced diabetic rats for 14 days. The ethyl acetate fraction was administered orally to the STZ diabetic rats 
at the doses of 200 and 400 mg/kg. Blood glucose level was measured according to glucose oxidase method. In order to determine 
hepatoprotective activity, changes in the levels of serum biomarker enzymes such as aspartate transaminase (AST), alanine transaminase 
(ALT), and serum alkaline phosphatase (SALP) were assessed in the ethyl acetate fraction treated diabetic rats and were compared 
with the levels in diabetic control rats. In addition, the antioxidant activity of ethyl acetate fraction was evaluated using various hepatic 
parameters such as thiobarbituric acid reactive substances (TBARS), reduced glutathione (GSH), superoxide dismutase (SOD), and 
catalase (CAT). It was found that administration of ethyl acetate fraction (200 and 400 mg/kg) produced a significant (P < 0.001) fall in 
fasting blood glucose level, TBARS, bilirubin, AST, ALT, and SALP, while elevating the GSH levels, and SOD and CAT activities in 
diabetic rats. Histopathologic studies also revealed the protective effect of ethyl acetate fraction on the liver tissues of diabetic rats. It 
was concluded from this study that the ethyl acetate fraction from ethanol extract of S. suaveolens modulates the activity of enzymatic 
and nonenzymatic antioxidants and enhances the defense against hepatic oxidative stress in STZ‑induced diabetic rats.
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oxidative stress has been found to be mainly due to an increased 
production of reactive oxygen species and a sharp reduction of 
antioxidant defenses.[2] A number of clinical studies suggest that 
the antioxidants in plants are key factors in reducing the incidence 
of diabetic complications.[3,4] Finding new natural sources of 
antioxidants with potential antidiabetic activity can be useful to 
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future therapy against diabetic mellitus.
Stereospermum suaveolens Roxb. (Bignoniaceae), popu‑
larly known as padiri in Tamil, is a large deciduous tree found 
throughout the moist parts of India. Traditionally, a decoction 
of the root is used for the treatment of inflammation, pain, fever, 
and asthma.[5,6] The flowers mixed with honey are given orally for 
the control of hiccups. In southern India, the bark is used in folk 
medicine for the treatment of diabetes.[5] The root extract is known 
to possess anticancer activity due to the presence of lapachol.[5,7] 
Previous phytochemical studies showed the presence of lapachol, 
dehydro‑a‑lapachone,[8] sterekunthal B, sterequinone C, and ste‑
reochenols A and B[9,10] in the bark, and stereolensin,[11] scutellarein, 
6‑hydroxy luteolin,[12]  dinatin  (4,5,7‑trihydroxyl‑6‑methoxyfla‑
von), and dinatin‑7‑glucuroniside[13] in the leaves. Previous stud‑
ies in our laboratory showed that crude ethanol extract and ethyl 
acetate fraction of S. suaveolens have antihyperglycemic effects 
in streptozotocin (STZ)‑induced diabetic rats.[14,15] No reports are 
available on the antioxidant activity of ethyl acetate fraction in 
the liver. Thus, the objective of the present study was to further 
explore our previous data by focusing now on the protective effect 
of S. suaveolens ethyl acetate fraction against oxidative stress in 
the liver of STZ‑induced diabetic rats.
MATERIALS AND METHODS
Chemicals
STZ, trichloroacetic acid (TCA), thiobarbituric acid (TBA), 
reduced glutathione (GSH), Tris‑HCl, sodium dodecyl sul‑
fate (SDS), nitro blue tetrazolium (NBT), reduced nicotinamide 
adenine dinucleotide (NADH), and phenazine methosulfate (PMS) 
were purchased from SISCO Research Laboratory, Mumbai, 
India. Glibenclamide was obtained from Prudence Pharma Chem, 
Ankeshwara, Gujarat, India. The solvents and chemicals used were 
of analytical grade.
Plant material
The plant was identified and authenticated by the Dr. Mohan, 
Scientist, Tropical Botanical Garden and Research Institute, 
Palode, Thiruvananthapuram district, Kerala, India, and a voucher 
specimen (TBS‑1) has been deposited in our laboratory for further 
reference. The bark of S. suaveolens (Roxb.) DC was collected dur‑
ing October 2006 from Palode forest, Tiruvananthapuram district. 
The bark of the plant was dried under shade and powdered with a 
mechanical grinder. The powdered plant material was then passed 
though sieve No. 40 and stored in an air‑tight container for future use.
Preparation of the crude plant extract and ethyl acetate 
fraction
The shade‑dried coarse powder bark of S. suaveolens (500 g) was 
packed in the Soxhlet extraction apparatus and extracted with 1.5 l 
of 95% ethanol at a temperature of 40‑50°C for 72 h. The extract 
was filtered and then concentrated to dryness in a rotary evaporator 
under reduced pressure at a temperature of 40°C. Then the crude 
ethanol extract of S. suavolens (EESS) (100 g) was dissolved in 
distilled water (500 ml) and fractionated with ethyl acetate.
The resultant black color residue was stored in a desiccator for use 
in subsequent experiments and considered as the ethyl acetate frac‑
tion. The yield of the ethyl acetate fraction was 16.52% w/w. Weighed 
amount of ethyl acetate fraction was suspended in 5% dimethyl 
sulfoxide (DMSO) in normal saline prior to oral administration.
Qualitative phytochemical analysis
Preliminary phytochemical screening was performed for the 
ethyl acetate fraction of EESS.[16‑18]
Animals
Male Wistar albino rats (weighing 180‑200 g) and male Swiss 
albino mice (20‑25 g) were purchased from M/S Ghosh Enter‑
prises, Kolkata, India. The animals were randomly grouped (n = 6), 
housed in polyacrylic cages (38 × 23 × 10 cm), and maintained 
under standard laboratory conditions (25 ± 2°C) with dark and light 
cycle (14/10 h). They were allowed free access to standard dry 
pellet diet (Hindustan Lever, Kolkata, India) and water ad libitum. 
The rats and mice were acclimatized to laboratory conditions for 
1 week before commencement of the experiment. Ethical clearance 
was obtained from Jadavpur University Animals Ethical Commit‑
tee for using animals in the present study.
Acute toxicity study
An acute oral toxicity study was performed as per Organisa‑
tion for Econamic Co‑operation and Development (OECD)‑423 
guidelines.[19] Male Swiss albino mice (20‑25 g) were randomly 
distributed to six groups of three each. The animals were fasted 
overnight and the ethyl acetate fraction was administered orally 
at a dose of up to 2000 mg/kg body weight. Mortality and gen‑
eral behavior such as grooming, sedation, hyperactivity, loss of 
righting reflex, respiratory rate, and convulsions of the animals 
were observed periodically for 72 h. The animals were observed 
continuously for the initial 2 h and intermittently for the next 6 h 
and then again at 24, 48, and 72 h, following drug administration.
Induction of diabetes
Rats were fasted for 16 h before the induction of diabetes with 
STZ. A freshly prepared solution of STZ (50 mg/kg) in 0.1 M cold 
citrate buffer (pH 4.5) was injected intraperitoneally in a volume of 
1 ml/kg,[20,21] and the control rats were injected with citrate buffer 
alone. In order to control hypoglycemia during the first day after 
STZ administration, diabetic rats were given 5% glucose solution 
orally. Hyperglycemia was confirmed by the elevated fasting glucose 
levels in blood, determined at 48 h and then on day 6 after injection. 
Rats with moderate diabetes exhibiting fasting blood glucose levels 
in the range of 260‑325 mg/100 ml were selected for the studies.
Treatment schedule
Rats were fasted for 16 h and divided into five groups of six 
each.[20]
The animals were treated orally, once daily, for 14 consecutive 
days, 7 days after STZ injection. The groupings are as follows:
Group I,  nondiabetic control: 5% DMSO in normal saline 
(5 ml/kg)
Group II,  STZ‑diabetic control: 5% DMSO in normal saline 
(5 ml/kg)
Group III, STZ‑diabetic rats: ethyl acetate fraction (200 mg/kg)
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Group IV, STZ‑diabetic rats: ethyl acetate fraction (400 mg/kg)
Group V, STZ‑diabetic standard: glibenclamide (0.5 mg/kg).
Fasting blood glucose level of each animal was determined 
on days 1, 4, 7, 10, and 15 after the initiation of treatment. On 
the 15th day, blood was collected from the overnight‑fasted rats 
by retro‑orbital bleeding, using microcapillary technique. Serum 
was separated and used for the determination of biochemical 
parameters such as aspartate transaminase (AST), alanine trans‑
aminase (ALT), serum alkaline phosphatase (SALP), bilirubin, 
and total proteins (using Automated Span Diagnostic Reagents, 
Mumbai, India).
Assessment of antioxidant activity
The  rats were  sacrificed on  the  15th day after collection of 
blood samples and their livers were excised immediately, washed 
in ice‑cold phosphate‑buffered saline (pH 7.4), blotted dry, and 
weighed. A 10% w/v of liver homogenate was prepared in 0.15 M 
Tris‑HCl buffer (pH 7.4). The homogenate was centrifuged at 
2000 × g for 20 min at 4°C to remove the cell debris and then the 
supernatant was centrifuged (REMI C‑24) at 12,000 × g for 1 h 
at 4°C. The supernatant obtained was used for the determination 
of lipid peroxidation,[19] reduced GSH,[22] superoxide dismutase 
(SOD),[23] and catalase (CAT).[24]
Histopathologic study
The fragments from the liver tissues were preserved in 10% 
neutral formalin solution and embedded in paraffin wax. Histo‑
logical sections were prepared, stained with Hematoxylin (H) 
and Eosin (E), mounted and observed under a light microscope.
Statistical analysis
The experimental data were expressed as mean ± SEM. The data 
were analyzed using analysis of variance (ANOVA) and Dunnett’s 
test. The results were considered statistically significant if P < 0.05.
RESULTS
Phytochemical screening
The qualitative phytochemical analysis of the ethyl acetate 
fraction revealed the presence of flavonoids, tannins, alkaloids, 
saponins, and glycosides.
Acute toxicity study
No mortality and toxic manifestations were observed up to the 
dose of 2000 mg/kg. Further dosing was not performed to estimate 
the LD50 (lethal dose) value. According to the OECD guidelines 
for the acute toxicity, an LD50 dose of 2000 mg/kg and above is 
categorized as unclassified, and hence, the drug is found to be safe. 
Based on the acute toxicity studies, the doses 200 and 400 mg/kg of 
the ethyl acetate fraction have been selected as the therapeutic dose.
Effect on blood glucose levels
Oral administration of a dose of 200 and 400 mg/kg of the 
ethyl acetate fraction of EESS to STZ‑induced diabetic rats sig‑
nificantly (P < 0.001) reduced the elevated fasting blood glucose 
levels, when compared to diabetic control rats. The effect of the 
ethyl acetate fraction of EESS on the fasting blood glucose levels 
in STZ‑induced diabetic rats is shown in Table 1.
Effect on serum biomarkers
In the present study, AST, ALT, SALP, and bilirubin levels 
were elevated and total protein level was decreased in diabetic 
control rats when compared with nondiabetic control rats, and the 
results are depicted in Table 2. Oral administration of ethyl acetate 
fraction of EESS for 14 days significantly (P < 0.001) decreased 
serum biomarker enzymes and bilirubin levels and increased total 
protein level.
Effects on hepatic in vivo antioxidant activities
Lipid peroxidation
STZ‑induced diabetic rats showed an increased level of 
thiobarbituric acid reactive substances (TBARS) in the liver 
[Table 3], as compared to nondiabetic rats. However, treat‑
ment  of  diabetic  rats with  ethyl  acetate  fraction  significant‑
ly (P < 0.001) decreased the concentration of TBARS in the 
liver tissue as compared to the respective diabetic control rats.
Reduced GSH content
The total GSH content decreased in STZ‑induced diabetic rats 
as compared to non‑diabetic rats. Administration of ethyl acetate 
fraction significantly (P < 0.001) increased the total GSH content 
in the liver when compared to the level in STZ‑induced diabetic 
control rats, and the results are shown in Table 3. 
Table 1. Effect of ethyl acetate fraction of Stereospermum suaveolens on the glucose level in STZ‑induced diabetic rats
Groups Serum glucose levels (mg/dl)
1st day 5th day 7th day 10th day 15th day
Nondiabetic control 
(5% DMSO in 0.9% NaCl, 5 ml/kg)
85.64±1.99 85.84±2.18 87.84±2.18 91.64±1.36 86.60±1.91
STZ‑induced diabetic control 
(5% DMSO in 0.9% NaCl, 5 ml/kg)
290.65±1.86a,** 294.80±2.35a,** 294.84±2.18a,** 299.2±1.46a,** 293.40±2.42a,**
STZ+ethyl acetate fraction 
(200 mg/kg)
264.81±1.96b,** 247.86±1.86b,** 211.84±2.18b,** 187.6±2.18b,** 135.42±1.99b,**
STZ+ethyl acetate fraction 
(400 mg/kg)
283.28±1.16b,** 226.56±1.30b,** 173.48±2.34b,** 132.5±2.51b,** 124.12±1.13b,**
STZ+glibenclamide (0.5 mg/kg) 286.50±6.35 173.50±6.35b,** 141.72±6.26b,** 126.21±6.61b,** 115±6.11b,**
Values are mean±SEM, six rats in each group, a,**P<0.001 as compared to nondiabetic control group, b,**P<0.001, when compared with STZ‑treated control 
group, STZ: Streptozotocin ; DMSO: Dimethyl sulfoxide
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SOD and CAT
In diabetic control rats, the activities of SOD and CAT were sig‑
nificantly (P < 0.001) decreased in the liver. The diabetic rats treat‑
ed with ethyl acetate fraction exhibited a significant (P < 0.001) 
increase in the activities of SOD and CAT in the liver, and the 
results are shown in Table 3.
Histopathologic studies of liver
Figure 1 presents the liver section of nondiabetic control rat, 
which shows normal cellular architecture with distinct hepatic 
cells, sinusoidal spaces, and well brought‑out central vein. 
The liver section of diabetic control rat shows several large 
areas  of  necrosis,  severe  inflammatory  cell  infiltration,  fatty 
change, and sinusoidal dilation and congestion [Figure 2]. His‑
topathologic examination of the livers of rats treated with ethyl 
acetate fraction and glibenclamide maintained normal lobular 
architecture and had mild fatty change, feathery degeneration, 
and only slight neutrophil infiltration almost comparable to the 
normal [Figures 3‑5].
DISCUSSION
Reactive oxygen species play an important role in the 
pathogenesis and development of complications of diabetes. 
In diabetes, hyperglycemia increases the generation of free 
radicals and the liver is overburdened due to oxidative stress, 
which may lead to anatomical changes with the impairment 
of antioxidant enzymes functions, thus affecting carbohydrate 
metabolism and the activities of serum biomarker enzymes.[23,24] 
Antioxidants originating from plants play an important role 
in inhibiting and scavenging the free radicals, thus providing 
protection to human beings against oxidative stress in diabe‑
tes. As a part of our ongoing research on the medicinal plant 
S. suaveolens, the present study establishes the protective effect 
of the ethyl acetate fraction from EESS on hepatic damage in 
STZ diabetic rats.
The STZ diabetic rats exhibited persistent hyperglycemia 
which is the main diabetogenic factor and contributes to the oxi‑
dative stress in the liver.[25]
The present data indicate that daily administration of ethyl 
acetate fraction (200 and 400 mg/kg) of EESS for 14 days signifi‑
cantly reduced hyperglycemia in STZ‑induced diabetic rats when 
compared to diabetic control rats in a dose‑dependent manner. This 
finding suggests that the ethyl acetate fraction of EESS had a potent 
antihyperglycemic activity in diabetic rats, which corresponded to 
the previous finding that the crude ethanol extract reduced blood 
glucose level in STZ diabetic rats.[14]
Assessment of liver function can be made by estimating the 
activities of serum biomarker enzymes such as AST, ALT, and 
SALP, which are originally present in higher concentration in the 
cytoplasm of hepatocytes. Serum bilirubin and the total protein 
levels, on the other hand, are related to the functions of hepatic 
cells.[26,27] The increased levels of AST, ALT, SALP, and serum 
bilirubin are conventional indicators of hepatocellular necrosis 
Table 2. Effect of ethyl acetate fraction of Stereospermum suaveolens on serum biomarkers in STZ‑induced diabetic rats
Groups AST (IU/dl) ALT (IU/dl) ALP (IU/dl) Total bilirubin (mg/dl) Total protein (g/dl)
Nondiabetic control 
(5% DMSO in 0.9% NaCl, 5 ml/kg)
57.07±4.12 61.60±2.56 121.18±3.03 0.85±0.10 7.14±0.23
STZ‑induced diabetic control 
(5% DMSO in 0.9% NaCl, 5 ml/kg)
146.80±6.30a,** 131.68±2.25a,** 245.42±5.51a,** 2.31±0.2a,** 3.26±0.45a,**
STZ+ethyl acetate fraction 
(200 mg/kg)
72.27±3.08b,** 78.61±3.25b,** 146.65±3.54b,** 1.12±0.09b,** 6.52±0.35b,**
STZ+ethyl acetate fraction 
(400 mg/kg)
64.62±2.94b,** 67.29±2.78b,** 131.40±1.51b,** 0.95±0.13b,** 7.64±0.45b,**
STZ+glibenclamide (0.5 mg/kg) 85.33±2.12b,** 98.50±6.09b,** 163.83±1.85b,** 1.24±0.09b,** 5.86±0.34b,**
Values are mean±SEM, six rats in each group, a,**P<0.001 as compared to nondiabetic control group, b,**P<0.001, when compared with STZ‑treated control 
group, STZ: Streptozotocin; AST: Aspartate transaminase; ALT: Alanine transaminase; DMSO: Dimethyl sulfoxide; ALP: Alkaline phosphatase
Table 3. Effect of ethyl acetate fraction of Stereospermum suaveolens on liver lipid peroxidation, glutathione, and antioxidants in STZ‑induced 
diabetic rats
Groups Lipid peroxidation 
(nmol of MDA/mg protein)
Glutathione 
(µM/g protein)
Superoxide dismutase 
(IU/mg protein)
Catalase (nmol of H2O2 
decomposed/min/mg protein)
Nondiabetic control 
(5% DMSO in 0.9% NaCl, 5 ml/kg)
14.23±0.51 51.28±1.01 10.49±0.68 61.54±1.75
STZ‑induced diabetic control 
(5% DMSO in 0.9% NaCl, 5 ml/kg)
31.49±0.81a,** 24.81±0.79a,** 4.65±0.17a,** 22.45±0.89a,**
STZ+ethyl acetate fraction 
(200 mg/kg)
20.92±0.52b,** 39.77±1.22b,** 6.01±0.12b,** 43.80±1.26b,**
STZ+ethyl acetate fraction 
(400 mg/kg)
16.29±0.65b,** 48.08±0.70b,** 9.47±0.37b,** 58.49±1.84b,**
STZ+glibenclamide (0.5 mg/kg) 22.76±0.40b,** 38.83±1.37b,** 7.93±0.47b,** 46.33±1.24b,**
Values are mean±SEM, six rats in each group, a,**P<0.001 as compared to nondiabetic control group, b,**P<0.001, when compared with STZ‑treated control 
group, DMSO: Dimethyl sulfoxide; STZ: Streptozotocin; MDA: Malondialdehyde
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caused by oxidative stress in diabetes.[28] In the present study, there 
was a significant rise in serum biomarker levels such as AST, ALT, 
and SALP in diabetic rats, which could be related to excessive ac‑
cumulation of amino acids (glutamate and alanine) in the serum 
of diabetic animals as a result of amino acid mobilization from 
protein stores.[29,30] Administration of fraction at the doses of 200 
and 400 mg/kg significantly decreased the AST, ALT, and SALP 
toward normal level, indicating the ethyl acetate fraction of EESS 
preserved the structural integrity of the hepatocellular membrane 
and liver cell damage caused by oxidative stress associated with 
diabetes, which is confirmed by histopathologic studies.
Abnormalities in serum total proteins and bilirubin are very 
common in hepatic toxicity. The rise in the levels of serum biliru‑
bin is the most sensitive and confirms the intensity of jaundice.[26] 
It was found that the ethyl acetate fraction treatment reduced 
elevated serum bilirubin and increased the level of total protein 
in STZ‑induced diabetes, indicating that the ethyl acetate fraction 
may prevent hepatic injury.
Figure 1. Liver section of nondiabetic control rat stained with Hematoxylin 
and Eosin shows normal hepatocytes with normal lobular architecture: 
(a) central vein; (b) normal hepatocytes; and (c) normal sinusoids
Figure 2. Liver section of STZ‑induced diabetic control rat stained with 
Hematoxylin  and Eosin  is  shown:  (a)  severe  necrosis;  (b)  infiltrated 
inflammatory cell with fatty change; and (c) sinusoidal dilation
Figure 3. Liver section of ethyl acetate fraction (200 mg/kg) + STZ 
treated rat stained with Hematoxylin and Eosin is shown: (a) feathery 
degeneration; (b) slight neutrophil infiltration, almost comparable to the 
normal part
Figure 4. Liver section of ethyl acetate fraction (400 mg/kg) + STZ 
treated rat stained with Hematoxylin and Eosin, showing normal lobular 
architecture
Figure 5. Liver section of glibenclamide + STZ treated rat stained 
with Hematoxylin and Eosin, showing mild degeneration with normal 
architecture
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Numerous studies have demonstrated that oxidative stress is 
a key pathogenic factor in the development of diabetic complica‑
tions.[31,32] Oxidative stress induces the production of highly reac‑
tive oxygen species that are toxic to the cell, particularly the cell 
membrane in which these radicals interact with the lipid bilayer 
and produce lipid peroxides.[32]
Lipid peroxidation appears to be a key element in the pro‑
duction of secondary complications in diabetes. In the present 
study, the oxidative stress, measured as levels of malondialde‑
hyde  (MDA), was  significantly  lower  (P < 0.001) in the liver 
of ethyl acetate fraction treated rats compared to that in diabetic 
control rats. This suggests that ethyl acetate fraction of EESS 
might protect the liver tissue from lipid peroxidation. Furthermore, 
enhanced oxidative stress due to diabetes may also result from a 
dysfunction in the defense system against free radicals, such as 
reduction in glutathione or inactivation of SOD and CAT.[33]
Glutathione, a tripeptide present in micromolar concentrations 
in all the cells, acts as an antioxidant and its decrease has been 
reported in diabetes mellitus.[33] GSH has an important role in the 
generation of cellular redox state and, consequently, the imbal‑
ance in reduced GSH to oxidized glutathione ratio is a putative 
indicator of cellular oxidative stress. The GSH levels were signifi‑
cantly (P < 0.001) decreased in the liver of diabetic control rats. 
Decreased glutathione levels in diabetes have been considered to 
be an indicator of increased oxidative stress.[34‑36] Treatment with 
ethyl acetate fraction improved the reduced GSH level as compared 
to that in STZ diabetic control rats, suggesting strengthening of 
antioxidant defenses in liver.
The cellular radical scavenging systems include the enzymes 
such as SOD, which scavenges the superoxide ion by catalyzing 
its dismutation, and CAT, a heme protein enzyme that removes 
hydrogen peroxide.[37] Therefore, reduction in the activity of these 
enzymes (SOD, CAT) results in a number of deleterious effects 
due to the accumulation of superoxide anion radicals and hydrogen 
peroxide. These antioxidant enzyme levels significantly increased 
after the treatment of STZ‑induced diabetic rats with the ethyl 
acetate fraction of EESS, indicating the free radical scavenging 
activity and its protective effect against hepatic tissue damage. The 
above in vivo antioxidant status reveals support to the protective 
action of ethyl acetate fraction against oxidative stress–induced 
alteration in the liver of diabetic rats.
Moreover, the phytochemical examination of ethyl acetate 
fraction of EESS indicates the presence of flavonoids, saponins, 
tannins, glycosides, and alkaloids. These phytochemicals have 
been proved to possess powerful antioxidant activities.[37‑39] The 
observed antioxidant effect of this plant may be attributed to the 
presence of these bioactive principles.
CONCLUSION
The present research clearly indicates that the ethyl acetate 
fraction of S. suaveolens enhances the activity of hepatic anti‑
oxidant enzymes in STZ‑induced diabetic rats, which play a key 
role in the defense mechanism against hepatic damage caused by 
free radicals during hyperglycemia. Further chemical and phar‑
macological investigations are in progress to isolate, identify, and 
characterize the active principle (s) as well as to pinpoint the exact 
molecular mechanism of ethyl acetate fraction of EESS involved 
in liver protection against oxidative stress in diabetes.
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